Stock Analiz

Spero Therapeutics, Inc. SPRO

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$1.00Market cap $58M
Open the interactive analysis →

Spero Therapeutics, Inc. (SPRO) is a healthcare company listed in the US with a market value of about $58M. In the twelve months to September 30, 2026 it had revenue of $42M and net income of -$30M, a net margin of -71.0%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 48% a year, a 5-year average ROIC of -52%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.

About Spero Therapeutics

Spero Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $335000 in 2016 to $67M in 2025, growth of about 80.1% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 57% over three years (dilution for shareholders). It spends 58% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.4
P/B74.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−30%

Growth and quality

Revenue growth (1 yr)39.2%
Revenue growth (5 yrs, per year)48.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-102.6%
ROIC (5-yr avg.)-52.3%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$42M$67M$48M$104M$54M$18M$9M$18M$4M$2M$335000
Net income-$30M$9M-$69M$23M$46M-$90M-$78M-$61M-$42M-$39M-$25M
Free cash flow——————-$86M-$50M-$42M-$39M-$30M
EPS (diluted)$-0.49$0.15$-1.27$0.43$-1.23$-2.91$-3.52$-3.35$-2.60$-17.82$-95.87
Net margin-71.0%12.8%-142.9%22.0%86.7%-491.9%-839.2%-335.6%-1051.4%-1957.7%-7609.2%
ROIC—9.9%-145.5%17.1%-51.0%-91.9%-56.5%-78.7%-37.1%-49.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $5.33, 433% above the current price; targets range from $4.00 to $6.00; the consensus rating is “Buy”; expected EPS is $-1.28 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Spero Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Spero Therapeutics pay a dividend?

Not currently.

Is Spero Therapeutics a good stock to buy?

We do not give buy or sell advice. Spero Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.